{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:45:19Z","timestamp":1793198719333,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX10722301-003"],"award-info":[{"award-number":["2018ZX10722301-003"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multidrug-resistant tuberculosis (MDR-TB) are unsatisfied to treat, pressing more effective and innovative treatment regimens. New efficient regimens for MDR-TB have obtained high treatment success rates. However, those regimens without drug susceptibility testing (DST) are also likely to contribute to the emergence of resistance. Precision treatments guided by DST might optimize the patients\u2019 treatment outcome individually and minimize resistance amplification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>TB-TRUST is a phase III, multicenter, open-label, randomized controlled clinical trial of non-inferiority comparing the treatment success rate between the World Health Organization (WHO) shorter regimen and the refined ultra-short regimen for fluoroquinolones and second-line injectable drugs susceptible rifampicin-resistant TB. The control arm uses the WHO injectable-containing shorter regimen for 36\u201344\u2009weeks depending on time of sputum smear conversion. The investigational arm uses a refined ultra-short regimen guided by molecular DST to pyrazinamide via whole-genome sequencing (WGS) to optimize the treatment of pyrazinamide-susceptible patients with levofloxacin, linezolid, cycloserine and pyrazinamide for 24\u201332\u2009weeks and pyrazinamide-resistant with levofloxacin, linezolid, cycloserine and clofazimine for 36\u201344\u2009weeks. The primary outcome is the treatment success rate without relapse at 84\u2009weeks after treatment initiation. Secondary outcomes include the time of sputum culture conversion and occurrence of adverse events. Assuming \u03b1\u2009=\u20090.025 level of significance (one-sided test), a power of 80%, a\u2009&lt;\u200910% difference in treatment success rate between control arm and investigational (80% vs. 82%), and a 5% lost follow-up rate, the number of participants per arm to show non-inferiority was calculated as 177(354 in total).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Rapid molecular testing distinguishes patients who are eligible for shorter regimen with fluoroquinolone and the WGS-guided results shorten the treatment to 6 months for pyrazinamide susceptible patients. It\u2019s foreseeable that not only novel developed medicines, but also traditional powerful medicines with the susceptibility confirmed by DST are the key factors to ensure the effect of anti-MDR-TB drugs. As a DST-guided precision treatment, TB-TRUST are expected to optimize therapy outcome in more patients who cannot afford the expensive new medicines and minimize and even avoid resistance amplification with the rational use of anti-TB drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trail registration<\/jats:title>\n                <jats:p>ClinicalTrial.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03867136?term=TB-TRUST&amp;draw=2&amp;rank=1\">NCT03867136<\/jats:ext-link>. Registered on March 7, 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-05870-w","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T06:40:00Z","timestamp":1613803200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Taoping","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"5870_CR1","volume-title":"Global tuberculosis report 2020","author":"WHO","year":"2020","unstructured":"WHO. Global tuberculosis report 2020. Geneva: World Health Organization; 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed 11 Nov 2020"},{"issue":"9","key":"5870_CR2","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1016\/S1473-3099(18)30104-X","volume":"18","author":"H Cox","year":"2018","unstructured":"Cox H, Hughes J, Black J, Nicol MP. Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible? Lancet Infect Dis. 2018;18(9):e282\u20137.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"5870_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Van Deun","year":"2010","unstructured":"Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5870_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5588\/ijtld.14.0535","volume":"19","author":"C Kuaban","year":"2015","unstructured":"Kuaban C, Noeske J, Rieder HL, A\u00eft-Khaled N, Abena Foe JL, Tr\u00e9bucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2015;19(5):517\u201324.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis"},{"issue":"10","key":"5870_CR5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.5588\/ijtld.13.0075","volume":"18","author":"A Piubello","year":"2014","unstructured":"Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2014;18(10):1188\u201394.","journal-title":"Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis."},{"issue":"13","key":"5870_CR6","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn AJ, Phillips PPJ, Meredith SK, Chiang C-Y, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201\u201313.","journal-title":"N Engl J Med"},{"key":"5870_CR7","volume-title":"Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB)","author":"Rapid Communication","year":"2018","unstructured":"Rapid Communication. Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). Geneva: World Health Organization; 2018. https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-TB-2018.18. Accessed 11 Nov 2020"},{"issue":"10","key":"5870_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893\u2013902.","journal-title":"N Engl J Med"},{"issue":"3","key":"5870_CR9","doi-asserted-by":"publisher","first-page":"1801770","DOI":"10.1183\/13993003.01770-2018","volume":"53","author":"F Sun","year":"2019","unstructured":"Sun F, Li Y, Chen Y, Guan W, Jiang X, Wang X, et al. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study. Eur Respir J. 2019;53(3):1801770.","journal-title":"Eur Respir J"},{"key":"5870_CR10","unstructured":"New Rapid Molecular Test For Tuberculosis Can Simultaneously Detect Resistance To First- And Second-Line Drugs - Jul 16, 2020. Available from: http:\/\/cepheid.mediaroom.com\/2020-07-16-New-Rapid-Molecular-Test-For-Tuberculosis-Can-Simultaneously-Detect-Resistance-To-First-And-Second-Line-Drugs. Accessed 11 Nov 2020."},{"issue":"1","key":"5870_CR11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41467-017-00721-2","volume":"8","author":"AN Yadon","year":"2017","unstructured":"Yadon AN, Maharaj K, Adamson JH, Lai Y-P, Sacchettini JC, Ioerger TR, et al. A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide. Nat Commun. 2017;8(1):588.","journal-title":"Nat Commun"},{"issue":"9","key":"5870_CR12","doi-asserted-by":"publisher","first-page":"1016.e1","DOI":"10.1016\/j.cmi.2017.12.012","volume":"24","author":"W Liu","year":"2018","unstructured":"Liu W, Chen J, Shen Y, Jin J, Wu J, Sun F, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect. 2018;24(9):1016.e1\u20135.","journal-title":"Clin Microbiol Infect"},{"key":"5870_CR13","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.3389\/fmicb.2019.01741","volume":"10","author":"X Chen","year":"2019","unstructured":"Chen X, He G, Wang S, Lin S, Chen J, Zhang W. Evaluation of whole-genome sequence method to diagnose resistance of 13 anti-tuberculosis drugs and characterize resistance genes in clinical multi-drug resistance mycobacterium tuberculosis isolates from China. Front Microbiol. 2019;10:1741.","journal-title":"Front Microbiol"},{"issue":"1","key":"5870_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2014.61","volume":"3","author":"W Shi","year":"2014","unstructured":"Shi W, Chen J, Feng J, Cui P, Zhang S, Weng X, et al. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect. 2014;3(1):1\u20138.","journal-title":"Emerg Microbes Infect."},{"issue":"9","key":"5870_CR15","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1093\/jac\/dkv150","volume":"70","author":"S Zhang","year":"2015","unstructured":"Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis : table 1. J Antimicrob Chemother. 2015;70(9):2507\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"5870_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/emi.2013.38","volume":"2","author":"S Zhang","year":"2013","unstructured":"Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2013;2(1):1\u20135.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"5870_CR17","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1128\/AAC.02941-15","volume":"60","author":"S Zhang","year":"2016","unstructured":"Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid. Antimicrob Agents Chemother. 2016;60(4):2542\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"5870_CR18","first-page":"e00940","volume":"61","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang J, Cui P, Zhang Y, Zhang W. Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008, and Rv1667c involved in pyrazinamide resistance in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61(8):e00940\u201317 e00940-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5870_CR19","first-page":"1","volume":"6","author":"S Zhang","year":"2017","unstructured":"Zhang S, Chen J, Shi W, Cui P, Zhang J, Cho S, et al. Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2017;6(1):1\u20132.","journal-title":"Emerg Microbes Infect."},{"key":"5870_CR20","volume-title":"WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment","author":"WHO","year":"2020","unstructured":"WHO. WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240007048. Accessed 11 Nov 2020"},{"issue":"1","key":"5870_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13063-018-3053-1","volume":"20","author":"M Lee","year":"2019","unstructured":"Lee M, Mok J, Kim DK, Shim TS, Koh W-J, Jeon D, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (treatment shortening of MDR-TB using existing and new drugs, MDR-END): study protocol for a phase II\/III, multicenter, randomized, open-label clinical trial. Trials. 2019;20(1):57.","journal-title":"Trials."},{"issue":"1","key":"5870_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1186\/s12879-019-4378-4","volume":"19","author":"U Khan","year":"2019","unstructured":"Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, et al. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019;19(1):733.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"5870_CR23","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.tips.2019.10.005","volume":"40","author":"P Gopal","year":"2019","unstructured":"Gopal P, Gr\u00fcber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci. 2019;40(12):930\u201340.","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"5870_CR24","doi-asserted-by":"publisher","first-page":"e00913","DOI":"10.1128\/AAC.00913-17","volume":"61","author":"S-Y Li","year":"2017","unstructured":"Li S-Y, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, et al. Bactericidal and sterilizing activity of a novel regimen with Bedaquiline, Pretomanid, Moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2017;61(9):e00913\u20137 e00913-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5870_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.advms.2015.09.007","volume":"61","author":"M Njire","year":"2016","unstructured":"Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W, et al. Pyrazinamide resistance in mycobacterium tuberculosis: review and update. Adv Med Sci. 2016;61(1):63\u201371.","journal-title":"Adv Med Sci"},{"issue":"2","key":"5870_CR26","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","volume":"47","author":"AS Pym","year":"2016","unstructured":"Pym AS, Diacon AH, Tang S-J, Conradie F, Danilovits M, Chuchottaworn C, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564\u201374.","journal-title":"Eur Respir J"},{"issue":"5","key":"5870_CR27","doi-asserted-by":"publisher","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","volume":"49","author":"SE Borisov","year":"2017","unstructured":"Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D\u2019Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387.","journal-title":"Eur Respir J"},{"key":"5870_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2020.04.043","volume":"96","author":"G He","year":"2020","unstructured":"He G, Li Y, Chen X, Chen J, Zhang W. Prediction of treatment outcomes for multidrug-resistant tuberculosis by whole-genome sequencing. Int J Infect Dis. 2020;96:68\u201372.","journal-title":"Int J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05870-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05870-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T06:40:20Z","timestamp":1613803220000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05870-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5870"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05870-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"25 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial received ethical approval from the Ethics Advisory Group of Huashan Hospital, Fudan University (approval number KY2019\u2013416). Prior to undergoing any study-specific procedures, participants must provide signed and dated written informed consent to participate this trail, agree to collection and use of their data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}